芒果视频下载

成立于1998年，知名阿膠品牌，以藥業/酒業為主導，集研發/生產/經營/投資/管理于一體的綜合性集團公司，產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類

1998年成立的輔仁藥業集團，是一家以藥業、酒業為主導，集研發、生產、經營、投資、管理于一體的綜合性集團公司。集(ji)團囊括河(he)南輔(fu)(fu)仁(ren)堂制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、河(he)南輔(fu)(fu)仁(ren)懷慶堂制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、開封(feng)制藥(yao)(yao)(yao)（集(ji)團）有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、開封(feng)豫港(gang)制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、開藥(yao)(yao)(yao)集(ji)團（開魯）制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、河(he)南同源(yuan)制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、輔(fu)(fu)仁(ren)醫藥(yao)(yao)(yao)科技開發(fa)(fa)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、輔(fu)(fu)仁(ren)藥(yao)(yao)(yao)業(ye)集(ji)團醫藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、輔(fu)(fu)仁(ren)藥(yao)(yao)(yao)業(ye)集(ji)團熙德隆(long)腫(zhong)瘤(liu)藥(yao)(yao)(yao)品(pin)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、北京(jing)遠策藥(yao)(yao)(yao)業(ye)有(you)(you)(you)(you)限(xian)(xian)(xian)責任公(gong)(gong)(gong)司、北京(jing)輔(fu)(fu)仁(ren)瑞輝生(sheng)物(wu)醫藥(yao)(yao)(yao)研究院、上(shang)海輔(fu)(fu)仁(ren)醫藥(yao)(yao)(yao)研發(fa)(fa)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、鄭州遠策生(sheng)物(wu)制藥(yao)(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司、河(he)南省(sheng)宋(song)河(he)酒業(ye)股份有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司及(ji)上(shang)市公(gong)(gong)(gong)司輔(fu)(fu)仁(ren)藥(yao)(yao)(yao)業(ye)集(ji)團制藥(yao)(yao)(yao)股份有(you)(you)(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司等多(duo)家全(quan)資、控(kong)股子(zi)公(gong)(gong)(gong)司。

集(ji)團(tuan)產品(pin)涵蓋了(le)中西藥(yao)(yao)制劑、生(sheng)物制藥(yao)(yao)、原料藥(yao)(yao)、保健食(shi)品(pin)等多個(ge)門類。2006年(nian)，隨著河南輔仁(ren)(ren)(ren)堂制藥(yao)(yao)有限公(gong)司成功(gong)實(shi)現(xian)上市，資(zi)本的力(li)量(liang)不僅把(ba)(ba)輔仁(ren)(ren)(ren)推向一個(ge)飛速發(fa)展(zhan)時(shi)期(qi)，其行業地位(wei)亦(yi)逐步(bu)提(ti)升。2017年(nian)12月29日，輔仁(ren)(ren)(ren)藥(yao)(yao)業重大(da)資(zi)產重組成功(gong)，把(ba)(ba)集(ji)團(tuan)優(you)質(zhi)資(zi)產——開封制藥(yao)(yao)（集(ji)團(tuan)）有限公(gong)司置(zhi)入(ru)輔仁(ren)(ren)(ren)藥(yao)(yao)業，使輔仁(ren)(ren)(ren)藥(yao)(yao)業跨入(ru)一個(ge)新的發(fa)展(zhan)階(jie)段(duan)。

“品種(zhong)為(wei)核心，并(bing)購(gou)為(wei)主線(xian)”的早(zao)期(qi)發(fa)展(zhan)戰(zhan)略讓輔(fu)仁藥業集團的產能和產品線(xian)在(zai)很短時間(jian)內(nei)飛(fei)速發(fa)展(zhan)。迄(qi)今，輔(fu)仁藥業集團已(yi)擁有(you)水針(zhen)劑(ji)、凍干(gan)粉針(zhen)劑(ji)、口服固體制(zhi)(zhi)劑(ji)等20多個劑(ji)型，1000余個品種(zhong)；制(zhi)(zhi)劑(ji)綜合(he)產能位居全國制(zhi)(zhi)藥行(xing)業前茅。2017新版醫(yi)保目錄(lu)(lu)輔(fu)仁藥業集團共入選578個品種(zhong)，較2009版目錄(lu)(lu)增(zeng)加(jia)(jia)品種(zhong)165個，增(zeng)幅(fu)39.95%，其(qi)中甲(jia)類(lei)入選364個，增(zeng)幅(fu)42.754%，乙類(lei)入選214個，增(zeng)幅(fu)35.44%。在(zai)國家衛健委正式(shi)發(fa)布《國家基本藥物目錄(lu)(lu)（2018年(nian)版）》中，輔(fu)仁藥業集團共有(you)阿莫西林克拉(la)維酸鉀干(gan)混懸劑(ji)、奧(ao)美拉(la)唑腸溶(rong)膠囊、注射用重組人干(gan)擾素(su)α2b等262個品規榜上有(you)名，較2012版目錄(lu)(lu)增(zeng)加(jia)(jia)75個，增(zeng)幅(fu)40.11%，成為(wei)全國入選品種(zhong)較多的制(zhi)(zhi)藥企業之一。

輔(fu)仁藥(yao)業集(ji)團一(yi)直遵循“濟世藥(yao)為(wei)輔(fu)、惠民(min)志在仁”的(de)企(qi)業理念，始終貫徹“產量讓(rang)位于(yu)質(zhi)(zhi)量、成(cheng)本讓(rang)位于(yu)質(zhi)(zhi)量”的(de)質(zhi)(zhi)量管(guan)理方針，本著“和而不(bu)同、化(hua)繁(fan)為(wei)簡、務實創新、濟世惠民(min)”的(de)企(qi)業價值觀，把(ba)“做一(yi)家(jia)實體型(xing)、科技(ji)型(xing)、國(guo)際型(xing)企(qi)業”作為(wei)自(zi)己的(de)企(qi)業定位，兼容(rong)并蓄(xu)，尊重(zhong)規律，踐行規則。

在企業(ye)并購的(de)(de)同時，輔仁藥(yao)業(ye)集(ji)團(tuan)投入(ru)巨資加強企業(ye)創(chuang)(chuang)新(xin)平(ping)臺(tai)建設，戰略性布局鄭州技術(shu)研(yan)(yan)發和(he)國(guo)際(ji)化合作(zuo)及產(chan)業(ye)化服(fu)務平(ping)臺(tai)、北(bei)京創(chuang)(chuang)新(xin)研(yan)(yan)發平(ping)臺(tai)、上(shang)海醫藥(yao)研(yan)(yan)發創(chuang)(chuang)新(xin)國(guo)際(ji)合作(zuo)平(ping)臺(tai)、美國(guo)新(xin)澤西、費城研(yan)(yan)發平(ping)臺(tai)四大(da)研(yan)(yan)發創(chuang)(chuang)新(xin)平(ping)臺(tai)，以及中(zhong)醫藥(yao)大(da)數據及人工(gong)智能中(zhong)醫研(yan)(yan)發平(ping)臺(tai)，更將在小(xiao)分(fen)子化學藥(yao)、大(da)分(fen)子生物藥(yao)研(yan)(yan)發和(he)中(zhong)醫藥(yao)傳承(cheng)創(chuang)(chuang)新(xin)方向同時發力(li)，開辟(pi)以研(yan)(yan)發驅動創(chuang)(chuang)新(xin)的(de)(de)發展新(xin)路徑。

目前，輔(fu)仁藥業集(ji)(ji)團支持創新研(yan)發面積達(da)11.3萬平方米(mi)，研(yan)發創新隊伍(wu)近(jin)1500人。同時，秉承“中(zhong)國市場(chang)、輔(fu)仁平臺、全球資(zi)源”的發展策略，輔(fu)仁藥業集(ji)(ji)團實現了從“百姓藥、輔(fu)仁造(zao)(zao)”到(dao)“創新藥、輔(fu)仁造(zao)(zao)”的可持續發展跨越，為客戶及(ji)整(zheng)個社會創造(zao)(zao)價值，健康中(zhong)國，服務世界。